Alterations of bone metabolism of patients with primary and platinum-sensitive recurrent tuboovarian carcinoma induced by platinum-based chemotherapy with and without bevacizumab

被引：0
|
作者：
Kurbacher, C. M. [1 ]
Herz, S. [1 ]
Kurbacher, A. T. [1 ]
Rhau, W. [1 ]
Kurbacher, J. A. [1 ]
机构：
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Germany
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1247
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Direct effects of platinum-based chemotherapy ± bevacizumab on the bone metabolism of patients with primary and platinum-sensitive recurrent tuboovarian carcinoma
    Kurbacher, C. M.
    Huhmann, A.
    Herz, S.
    Monreal, K.
    Kurbacher, J. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Expression of bone turnover markers in patients with tuboovarian carcinoma exposed to platinum-based chemotherapy ± bevacizumab
    Kurbacher, C. M.
    Huhmann, A.
    Herz, S.
    Kurbacher, A. T.
    Monreal, K.
    Kurbacher, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 750 - 750
  • [3] Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients
    Sato, Hiroki
    Tsukahara, Kiyoaki
    Okamoto, Isaku
    Katsube, Yasuaki
    Shimizu, Akira
    Kondo, Takahito
    Hanyu, Kenji
    Fushimi, Chihiro
    Okada, Takuro
    Miura, Kouki
    ACTA OTO-LARYNGOLOGICA, 2019, 139 (02) : 201 - 205
  • [4] Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
    Zhu, Yunshu
    Yang, Sheng
    Zhou, Shengyu
    Yang, Jianliang
    Qin, Yan
    Gui, Lin
    Shi, Yuankai
    He, Xiaohui
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [5] Benefit for female Patients: Bevacizumab in recurrent Platinum-sensitive Ovarian Cancer
    Schmalfeldt, Barbara
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (01): : A7 - A8
  • [6] TRABECTEDIN ALLOWS RETREATMENT WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY (PRR) AND PARTIALLY PLATINUM-SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC)
    Callata, H.
    Manzano, A.
    Sanchiz, B.
    Alonso, T.
    Gajate, P.
    Cabezas, S.
    Sotelo, M.
    Aguado, C.
    Diaz-Rubio, E.
    Casado, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [7] Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
    Nakao, Takehiro
    Harano, Kenichi
    Wakabayashi, Masashi
    Naito, Yoichi
    Tanabe, Hiroshi
    Mukohara, Toru
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 55
  • [8] Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment
    Ledermann, J. A.
    Oza, A. M.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J. I.
    Clamp, A. R.
    Scambia, G.
    Leary, A.
    Holloway, R. W.
    Amenedo Gancedo, M.
    Fong, P. C.
    Goh, J. C.
    O'Malley, D. M.
    Cameron, T.
    Maloney, L.
    Goble, S.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer
    Markman, M
    GYNECOLOGIC ONCOLOGY, 1999, 73 (03) : 469 - 470
  • [10] Maintenance chemotherapy among patients with platinum-sensitive recurrent ovarian cancer
    Yang Qiuan
    Zhao Weiping
    Wang QingweiThe Cancer Center of the Affiliated Hospital of Shandong Medical University
    现代妇产科进展, 1999, (04) : 394 - 395
12345